Tradestie Institutional Equity Comparison Engine

AARD vs EKSO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AARD Overall Edge

AARD Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aardvark Therapeutics, Inc. Common Stock (AARD) driven by superior Growth & Margin, Options & Structure while EKSO counters with relative strength in Momentum & Technical. Fundamentally, AARD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EKSO at N/M Forward P/E and -119.7% operating margin (-38.3% YoY). In options structure, AARD sits in UNCLASSIFIED (26th %ile IV; Dealer Gamma Walls on Pro) against EKSO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AARD N/M vs EKSO N/M Fwd P/E
Growth & Margin Winner AARD
Op Margin 0.0% vs -119.7% ยท YoY +0.0% vs -38.3%
Momentum & Technical Winner EKSO
1Y -91.2% vs +62.6% ยท 52W Pos 0% vs 87%
Options & Structure Winner AARD
UNCLASSIFIED (26th %ile IV) vs UNCLASSIFIED (N/A IV)
AARD NASDAQ
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.74% 1D
Market Cap $21.9M
1M Return -76.64%
1Y Return -91.18%
Forward P/E N/M
Unified AI Score
45.9 / 100 HOLD
Tech 35.0 Fund 54.0 Flow 68.0 Mom 59.0
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
1M Return +25.53%
1Y Return +62.6%
Forward P/E N/M
Unified AI Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AARD -91.18% EKSO +62.6% Spread: +242.42 pp (EKSO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AARD TTM Op. Margin: 0.0% EKSO TTM Op. Margin: -119.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AARD vs EKSO. Trailing 12-month operating profitability (AARD 0.0% vs EKSO -119.7%) and valuation multiples (AARD N/M vs EKSO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AARD (4) vs EKSO (4)
Institutional Metric AARD EKSO Criterion Row Winner
Market Capitalization Scale $21.9M $42.0M Larger Scale EKSO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -38.3% Higher Growth AARD
Operating Margin (TTM) Profitability 0.0% -119.7% Higher Margin AARD
Net Profit Margin Profitability 0.0% -91.4% Higher Margin AARD
Return on Equity (ROE) Capital Efficiency -66.0% -107.6% Higher ROE AARD
52-Week Range Position Momentum 0% ($1โ€“$17) 87% ($0โ€“$14) Stronger Trend EKSO
Beta / 30D Volatility Risk Regime 3.84ฮฒ ยท 284% Vol 2.16ฮฒ ยท 76% Vol Lower Realized Risk EKSO
Unified Institutional Score Composite Signal 45.9 / 100 (HOLD) 58.1 / 100 (HOLD) Higher Composite EKSO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AARD vs EKSO Buy Guide
AARD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AARD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EKSO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EKSO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AARD nor EKSO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.